{
    "id": 386,
    "fullName": "NRAS wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type NRAS indicates that no mutation has been detected within the NRAS gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4893,
        "geneSymbol": "NRAS",
        "terms": [
            "NRAS",
            "ALPS4",
            "CMNS",
            "N-ras",
            "NCMS",
            "NRAS1",
            "NS6"
        ]
    },
    "variant": "wild-type",
    "createDate": "03/13/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8538,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an NRAS wild-type melanoma cell line demonstrated inhibition of cell growth when treated with Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8535,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8545,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an NRAS wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17406,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is FDA approved for metastatic colorectal patients that are NRAS wild-type, as detected by a companion diagnostic (FDA.gov).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15480,
                    "pubMedId": null,
                    "title": "Vectibix (panitumumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3269,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3357,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3760,
                    "pubMedId": 25605843,
                    "title": "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605843"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5625,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type NRAS (PMID: 23039341).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3796,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",
            "molecularProfile": {
                "id": 15931,
                "profileName": "BRAF mut NRAS wild-type"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7952,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7960,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3798,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10122,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5400,
                "therapyName": "Binimetinib + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4934,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4944,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5563,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",
            "molecularProfile": {
                "id": 19839,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5108,
                    "pubMedId": 27002107,
                    "title": "Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27002107"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9442,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF and NRAS wild-type and expressing DTL demonstrated tumor growth inhibition in xenograft models when treated with MLN4924 (PMID: 27333051).",
            "molecularProfile": {
                "id": 26849,
                "profileName": "BRAF wild-type DTL pos NRAS wild-type"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17022,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16976,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2184,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFIRINOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17019,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5573,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab",
                "synonyms": "Panitumumab + FOLFIRI"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16986,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17029,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17020,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17023,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16985,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17030,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17015,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 8360,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOXIRI"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13278,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Avastin (bevacizumab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 32.2 mo and response rate of 75% (43/57), however, resulted in a 10-mo PFS rate of 40.4% (23/57), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 6803,
                "therapyName": "Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + Bevacizumab + FOLFIRI "
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11041,
                    "pubMedId": 29450468,
                    "title": "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29450468"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17021,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1986,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16490,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Erbitux (cetuximab) and Camptosar (irinotecan) rechallenge resulted in a response rate of 21% (6/28, 6 partial responses) and a disease control rate of 54% (15/28) in RAS and BRAF wild-type colorectal cancer patients that acquired resistance to first-line cetuximab and irinotican-based therapy, patients with wild-type RAS in ctDNA at baseline achieved longer median progression-free survival (4.0 vs 1.9 mo, HR=0.44, p=0.03) compared to those with mutant RAS (PMID: 30476968; NCT02296203).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14554,
                    "pubMedId": 30476968,
                    "title": "Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30476968"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17017,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1986,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOX"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17024,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5573,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab",
                "synonyms": "Panitumumab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17018,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17016,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic rectum cancer patients with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2184,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFIRINOX"
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16975,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 8360,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOXIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13276,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Erbitux (cetuximab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 33.2 mo and response rate of 68% (40/59), however, resulted in a 10-mo PFS rate of 50.8% (30/59), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11041,
                    "pubMedId": 29450468,
                    "title": "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29450468"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16384,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in disease stabilization in one\u00a0model,\u00a0but was ineffective in\u00a0the second\u00a0model\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16381,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) amplification was identified in 36% (4/11) of unique colorectal cancer patient-derived xenografts (PDX) resistant to Erbitux (cetuximab)\u00a0treatment\u00a0and wild-type for KRAS, BRAF, PIK3CA, and NRAS compared to 2 to 3%\u00a0(3/137, 3/112 in archival specimens)\u00a0in an unselected population (PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16382,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study,\u00a0two\u00a0patient-derived xenograft\u00a0(PDX) models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA were resistant to Perjeta (pertuzumab) treatment (PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16386,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Tykerb (lapatinib) and Erbitux (cetuximab) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in reduced tumor\u00a0volume\u00a0for both models\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 1672,
                "therapyName": "Cetuximab + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16383,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Erbitux (cetuximab) and Perjeta (pertuzumab) treatment of patient-derived xenograft (PDX) models with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in a brief delay of tumor growth\u00a0in one model\u00a0and disease stabilization in a second\u00a0model\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 8015,
                "therapyName": "Cetuximab + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16385,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Tykerb (lapatinib) and Perjeta (pertuzumab) treatment of two patient-derived xenograft\u00a0(PDX)\u00a0models,\u00a0with resistance to Erbitux (cetuximab) monotherapy, harboring ERBB2 (HER2) amplification and wild-type for KRAS, BRAF, NRAS, and PIK3CA resulted in reduced tumor\u00a0volume for both\u00a0models\u00a0(PMID: 22586653).",
            "molecularProfile": {
                "id": 31620,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type"
            },
            "therapy": {
                "id": 5958,
                "therapyName": "Lapatinib + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9255,
                    "pubMedId": 22586653,
                    "title": "A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586653"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16982,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS, BRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35567,
                "profileName": "BRAF wild-type ERBB2 amp NRAS wild-type"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16983,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS, BBRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35567,
                "profileName": "BRAF wild-type ERBB2 amp NRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16996,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and wild-type NRAS and BRAF (NCCN.org).",
            "molecularProfile": {
                "id": 35567,
                "profileName": "BRAF wild-type ERBB2 amp NRAS wild-type"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16995,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and wild-type NRAS and BRAF (NCCN.org).",
            "molecularProfile": {
                "id": 35567,
                "profileName": "BRAF wild-type ERBB2 amp NRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 481,
            "profileName": "NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15931,
            "profileName": "BRAF mut NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15933,
            "profileName": "BRAF wild-type NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19839,
            "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26849,
            "profileName": "BRAF wild-type DTL pos NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29053,
            "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31620,
            "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type NRAS wild-type PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31649,
            "profileName": "BRAF V600E KRAS wild-type NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32292,
            "profileName": "ERBB2 amp NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35567,
            "profileName": "BRAF wild-type ERBB2 amp NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}